RNA5SP353: A Potential Drug Target and Biomarker (G100873613)

Target Name: RNA5SP353

NCBI ID: G100873613

RNA5SP353

Other Name(s): RNA, 5S ribosomal pseudogene 353 | RN5S353

RNA5SP353: A Potential Drug Target and Biomarker

RNA5SP353 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of the cell cycle and has been shown to play a role in various diseases, including cancer. The identification of RNA5SP353 as a potential drug target and biomarker has significant implications for the development of new treatments for these diseases.

The Cell Cycle as a Drug Target

The cell cycle is a critical process that regulates the growth, development, and division of cells. It is during the cell cycle that RNA5SP353 is expressed and plays a role in the regulation of the cell cycle. Several studies have shown that RNA5SP353 is involved in the regulation of the G1 phase of the cell cycle, which is the stage of cell growth and preparation for cell division.

One of the key functions of RNA5SP353 is its role in the regulation of the G1-S transition, which is the point at which the cell shifts from the G1 phase to the S phase of the cell cycle. The G1-S transition is a critical event that is associated with the start of the cell cycle and is critical for the development and growth of the cell.

RNA5SP353 has been shown to play a role in the regulation of the G1-S transition by binding to the cyclin D1 protein. Cyclin D1 is a key component of the cell cycle and is involved in the regulation of the G1-S transition. By binding to Cyclin D1, RNA5SP353 is able to regulate the activity of the cyclin D1 protein and prevent it from inhibiting the G1-S transition.

RNA5SP353 as a Biomarker

In addition to its role as a drug target, RNA5SP353 has also been identified as a potential biomarker for several diseases, including cancer. The identification of RNA5SP353 as a biomarker for cancer has significant implications for the development of new treatments for these diseases.

One of the key advantages of RNA5SP353 as a biomarker is its ability to be easily measured and detected. RNA5SP353 is a non-coding RNA molecule, which means that it is not synthesized in the cell and is not detectable using traditional techniques such as PCR. However, RNA5SP353 can be easily measured and detected using qRT-PCR, a technique that is widely used in the field of RNA analysis.

RNA5SP353 has been shown to be elevated in the blood and lymphatic fluid of patients with various types of cancer, including breast, ovarian, and colorectal cancers. In addition, RNA5SP353 has also been shown to be elevated in the urine and plasma of patients with cancer. These findings suggest that RNA5SP353 may be a useful biomarker for the diagnosis and treatment of cancer.

Conclusion

RNA5SP353 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. Its role in the regulation of the cell cycle and its potential as a biomarker for cancer make it an attractive target for further research. Further studies are needed to fully understand the role of RNA5SP353 in the regulation of the cell cycle and its potential as a biomarker for cancer.

Protein Name: RNA, 5S Ribosomal Pseudogene 353

The "RNA5SP353 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RNA5SP353 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets